Aprea Therapeutics
APRE
64 hedge funds and large institutions have $639M invested in Aprea Therapeutics in 2020 Q2 according to their latest regulatory filings, with 22 funds opening new positions, 25 increasing their positions, 10 reducing their positions, and 8 closing their positions.
175% more first-time investments, than exits
New positions opened: 22 | Existing positions closed: 8
150% more repeat investments, than reductions
Existing positions increased: 25 | Existing positions reduced: 10
50% more funds holding in top 10
Funds holding in top 10: 2 → 3 (+1)
36% more capital invested
Capital invested by funds: $468M → $639M (+$171M)
28% more funds holding
Funds holding: 50 → 64 (+14)
0.71% more ownership
Funds ownership: 3.2% → 3.91% (+0.71%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
VVM
Versant Venture Management
San Francisco,
California
|
+$60.8M |
| 2 |
CCM
Consonance Capital Management
New York
|
+$41.1M |
| 3 |
Vanguard Group
Malvern,
Pennsylvania
|
+$11M |
| 4 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$10.3M |
| 5 |
SFM
Sphera Funds Management
Tel Aviv,
Israel
|
+$5.19M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
5VM
5AM Venture Management
San Francisco,
California
|
-$21M |
| 2 |
SAM
Sectoral Asset Management
Montreal,
Quebec, Canada
|
-$18.2M |
| 3 |
Janus Henderson Group
London,
United Kingdom
|
-$9.17M |
| 4 |
EI
EAM Investors
Solana Beach,
California
|
-$2.37M |
| 5 |
EGI
EAM Global Investors
Solana Beach,
California
|
-$1.33M |
APRE Hedge Fund Activity: Q2 2020 in Review
64 of the 4,877 institutional investors tracked by Wall St. Rank reported a position in Aprea Therapeutics (APRE) for Q2 2020, worth a combined $639M — up 36% from $468M a quarter earlier.
Buyers outnumbered sellers: 22 funds opened new APRE positions and 8 closed out — a net gain of 14 holders — while 25 added to existing stakes and 10 trimmed.
The largest buyer was Versant Venture Management, opening a new position worth an estimated $60.8M. The largest seller was 5AM Venture Management, cutting an estimated $21M.
- 64 institutional investors held Aprea Therapeutics (APRE) as of Q2 2020, up from 50 in Q1 2020.
- Funds reported $639M of Aprea Therapeutics stock for Q2 2020, up 36% quarter-over-quarter.
- 22 funds opened new Aprea Therapeutics positions in Q2 2020 and 8 closed out, a net change of +14 holders.
- The largest Aprea Therapeutics buyer in Q2 2020 was Versant Venture Management, an estimated $60.8M added.
- The largest Aprea Therapeutics seller in Q2 2020 was 5AM Venture Management, an estimated $21M sold.
Based on aggregated 13F filings for Q2 2020.